Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura’s main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25 billion.
| Description | Report Date | Published |
|---|---|---|
| Annual Report 2012 | 31-03-2012 | 25-04-2012 |
| Annual Report 2011 | 31-03-2011 | 22-05-2011 |
| Annual Report 2010 | 31-03-2010 | 06-06-2010 |
| Annual Report 2009 | 31-03-2009 | 18-05-2009 |
| Annual Report 2008 | 31-03-2008 | 21-05-2008 |
| Annual Report 2007 | 31-03-2007 | 22-05-2007 |
| Annual Report 2006 | 31-03-2006 | 24-05-2006 |
| Annual Report 2005 | 31-03-2005 | 24-06-2005 |
| Description | Report Date | Published |
|---|---|---|
| Interim Report 2012 | 30-09-2012 | 19-11-2012 |
| Interim Report 2011 | 30-09-2011 | 13-11-2011 |
| Interim Report 2010 | 30-09-2010 | 15-11-2010 |
| Interim Report 2009 | 30-09-2009 | 26-11-2009 |
| Interim Report 2008 | 30-09-2008 | 23-11-2008 |
| Interim Report 2007 | 30-09-2007 | 26-11-2007 |
| Interim Report 2006 | 30-09-2006 | 17-11-2006 |
| Interim Report 2005 | 30-09-2005 | 16-11-2005 |
| Description |
|---|
| Investor Relations |
| Presentations |
| Events Calendar |
| Home |
| Results Index |
| Contacts |
| Type | Dividend | Payment Date |
|---|